Hemostatic composition
First Claim
Patent Images
1. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising:
- a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof;
b) a predetermined amount of a particulate material in said medium;
c) said particulate material comprising core particles with a coating;
d) said core particles having an average particle size of about 5 nm to 10 μ
m;
e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition;
f) said coating comprising procoagulant molecules; and
g) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and
h) an optional surfactant or dispersant.
1 Assignment
0 Petitions
Accused Products
Abstract
A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 μm, and the coating is one of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, or a combination thereof.
-
Citations
31 Claims
-
1. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising:
-
a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μ
m;e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; and g) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and h) an optional surfactant or dispersant. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 30)
-
-
11. A magnetic hemostatic fluid suitable for controlling external or internal bleeding in a subject, comprising:
-
a) a biocompatible and non-toxic carrier fluid selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a magnetic particulate material in said carrier fluid; c) said particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 μ
m;d) said core particles having an average particle size of about 5 nm to 10 μ
m;e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the hemostatic fluid; f) said core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; g) said coating comprising procoagulant molecules; and h) an optional surfactant or dispersant. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 26, 31)
-
-
21. A method of controlling bleeding in a subject in need thereof, comprising the steps of:
-
a) administering to a subject having internal or external bleeding a predetermined amount of a hemostatic fluid; b) the hemostatic fluid, comprising; i) a biocompatible and non-toxic carrier fluid selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; ii) a predetermined amount of a magnetic particulate material in the fluid; iii) the particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 μ
m;iv) the core particles having an average particle size of about 5 nm to 10 μ
m;v) the concentration of the particulate material being about 0.1% to 70% (w/w) of the hemostatic fluid; vi) the core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; vii) the coating comprising; and viii) an optional surfactant or dispersant; c) applying a magnetic field adjacent the site of a lesion causing the bleeding so as to form a cluster of the particulate material for thereby controlling the flow of blood through the lesion. - View Dependent Claims (27)
-
-
22. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising:
-
a) a carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μ
m;e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; g) said coating further comprising one polymer member selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof; and h) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and i) an optional surfactant or dispersant.
-
-
23. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising:
-
a) a carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μ
m;e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising a member biocompatible and non-toxic to blood cells; g) said member comprising procoagulant molecules; and h) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and i) an optional surfactant or dispersant. - View Dependent Claims (28)
-
-
24. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising:
-
a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of more than 500 nm to about 10 μ
m;e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; and g) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and h) an optional surfactant or dispersant. - View Dependent Claims (29)
-
Specification